Mast To Develop Vepoloxamer (MST-188) In Chronic Heart Failure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
Mast Therapeutics (MSTX) to Develop Vepoloxamer (MST-188) to Treat Chronic Heart Failure
March 23, 2015 8:03 AM EDTMast Therapeutics (NYSE: MSTX) today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure. Encouraged by recently reported nonclinical results and input from experts in the field, the Company expects to begin dosing in a Phase 2 study of vepoloxamer in patients with chronic heart failure in the third quarter of this year.
Wilson S. Colucci M.D., Professor of Medicine and Physiology and Chief of Cardiovascular Medicine at Boston University School of Medicine said: "The results from studies in experimental heart failure are encouraging and support... More
